Literature DB >> 21357621

Pain perception during and after VNUS ClosureFAST™ procedure.

M T Roos1, B L S Borger van der Burg, J J Wever.   

Abstract

The objective of the study was first to quantify the level of pain that patients experience during VNUS ClosureFAST™ and in the first week following treatment. Secondly, to investigate the use of pain medication. Thirdly, to identify after how many days patients return to daily activities and whether pain is a factor of influence. A prospective descriptive cohort study was carried out. In all, 104 consecutive VNUS ClosureFAST procedures for greater saphenous vein (GSV) incompetence between 18 May and 28 August 2009 in the HagaZiekenhuis were included. A visual analogue score (VAS) was recorded immediately after the procedure. These patients were asked to register pain scores during the week following the procedure, the amount of pain medication if used and the time elapsed between the procedures and resuming daily activities. The average VAS score during the VNUS Closure procedure was four. The first three days after the procedure the VAS score was 2. After four days, the average score was 1. The average return to daily activities was on day two after the procedure. In total, 24% of all patients used paracetamol after the procedure. In summary, VNUS ClosureFAST procedure for GSV incompetence is not a painless treatment. After an average of two days, patients return to their daily activities. Pain does not seem to be a major factor in the resumption. Seventy-six percent of patients do not use any pain medication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357621     DOI: 10.1258/phleb.2010.010016

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  1 in total

Review 1.  Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter.

Authors:  Simon A Braithwaite; Bruce D Braithwaite
Journal:  Med Devices (Auckl)       Date:  2014-06-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.